No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NTLA240719C20000
- 2.40
- -2.18-47.60%
15min DelayClose Jun 28 15:59 ET
2.40High2.40Low
2.40Open4.58Pre Close2 Volume336 Open Interest20.00Strike Price480.00Turnover87.67%IV0.09%PremiumJul 19, 2024Expiry Date2.38Intrinsic Value100Multiplier19DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.7480Delta0.0701Gamma6.99Leverage Ratio-0.0393Theta0.0073Rho5.23Eff Leverage0.0166Vega
Intraday
- 5D
- Daily
News
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73
On Jun 27, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $24 to $73.BMO Capital analyst Kostas Biliouris maintains with a buy ra
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market.
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $95
On Jun 26, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $29 to $95.Citi analyst David Lebovitz maintains with a hold rating, an
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Express News | Intellia Therapeutics Inc - Glenn Goddard to Step Down as CFO Effective June 30, 2024
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
$Berkshire Hathaway 13F(LIST2999.US$ $Berkshire Hathaway-A(BRK.A.US$ $Berkshire Hathaway-B(BRK.B.US$ $ARK Innovation ETF(ARKK.US$ $Coinbase(COIN.US$ $Apple(AAPL.US$ $Bank of America(BAC.US$ $American Express(AXP.US$ $S&P 500 Index(.SPX.US$ $CRISPR Therapeutics(CRSP.US$ $Intellia Therapeutics(NTLA.US$
2
2
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
Read more